Key result
Outpatient treatment with apixaban for VTE was associated with significantly lower risks of major bleeding (by 27-39%), CRNM bleeding (by 17-28%), and recurrent VTE (by 25-39%) compared to warfarin.
Why the study?
To extend previous research by comparing bleeding and recurrent VTE outcomes between apixaban and warfarin over time and within selected subgroups in a real-world setting.
Does apixaban reduce bleeding and recurrent VTE compared to warfarin plus parenteral anticoagulant bridge therapy in outpatients with VTE?
Cohort (n=55,641)
Yes
Does apixaban reduce bleeding and recurrent VTE compared to warfarin plus parenteral anticoagulant bridge therapy in outpatients with VTE?
Effect estimate: adjusted risks lower by 27% to 39% (major bleeding), 17% to 28% (CRNM bleeding), and 25% to 39% (recurrent VTE)
p-value: p=≤ .01
In a real-world US claims cohort, outpatient treatment of VTE with apixaban was associated with significantly lower risks of major bleeding, CRNM bleeding, and recurrent VTE compared to warfarin.
Authors
No takes yet. Share an insight, caveat, or question.
Supports apixaban preference for outpatient VTE; extends real-world data but leaves open need for RCTs.
Weycker et al. (2020) conducted a cohort in Venous thromboembolism (VTE) (n=55,641). Apixaban vs. Warfarin (plus parenteral anticoagulant bridge therapy) was evaluated on Major bleeding, clinically relevant nonmajor (CRNM) bleeding, and recurrent VTE (adjusted risks lower by 27% to 39% (major bleeding), 17% to 28% (CRNM bleeding), and 25% to 39% (recurrent VTE), p=≤ .01). Outpatient treatment with apixaban for VTE was associated with significantly lower risks of major bleeding (by 27-39%), CRNM bleeding (by 17-28%), and recurrent VTE (by 25-39%) compared to warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: